TransMedics Q3 revenue $66.4M (+159% YoY); raises FY2023 guidance to $222-230M

TransMedics Group, Inc.

2023-Q3 EPS reported -$0.89 revenue$160,449,000

Revenue $66.4M, up 159% YoY; includes $2.1M from new aviation business and $1.6M non-recurring charter revenue.
Net loss widened to $25.4M from $7.4M, driven by $29.2M non-recurring acquisition costs including $27.2M in-process R&D charge.
Gross margin 61% vs 71% a year ago, impacted by Summit Aviation transition and legacy charter exit costs.
Cash $427.1M as of Sep 30; full-year 2023 revenue guidance raised to $222-230M from prior $180-190M.
Summit Aviation acquisition closed, adding aviation service to organ transplant logistics offering.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported quarter ended September 30, 2023 results: revenue $66.4 million. Guidance raised.

Period: quarter ended September 30, 2023
Revenue: $66.4 million
Guidance: raised
Result: reported results

Exact text from the filing

therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023. Recent Highlights ▪ Net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the third quarter of 2022, including $1.6 million non-recurring charter revenue ▪ Closed acquisition of Summit Aviation,

View on SEC.gov

Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-059424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.